Diabetic Nephropathy with Proteinuria Is the Risk of Indigestion Symptoms in Patients with Diabetes Mellitus—A Multicenter Survey in Japan

Patients with end stage renal disease frequently show indigestionsymptoms as a result of uremia. However, the association between the indigestionsymptoms and the earlier stage of diabetic nephropathyis unclear. Therefore we conducted a multicenter study using self-administered questionnaires: the Gastrointestinal Symptom Rating Scale (GSRS).Patients were type1 or type 2 DM between 20-85 years old treated in 2 hospitals and 3 clinics in Yokohama and Tokyo during June 2016 to January 2017. We excluded patients if they were either 1) pregnant or 2) suffering from malignant disease or digestive disease. We defined diabetic nephropathyas stage 3 or later and clinically significant indigestionsymptoms (CSIS) as GSRS≧3. We analyzed the association between diabetic nephropathyand CSIS.In total of 722 patients, 430 (61%) were male and 36 (5%) were Type 1 DM. Mean age was 65 years old, mean BMI was 25.0, mean HbA1c was 7.5% and mean duration of DM was 155 months. As for diabetic microangiopathy, 177 (26%) had nephropathy, 186 (30%) had peripheral neuropathy, 180 (29%) had retinopathy. GLP-1 receptor agonists were used in 62 (8.8%) patients. In comparison between patients with and without CSIS, age, BMI, HbA1c were not different. Duration of DM was longer in CSIS (193 ± 19 vs. 153 ± 5 months, p=0.046). Presence of diabetic nephropathywas associated with CSIS (OR=2.08, 95% CI: 1.10-3.91), in contrast, that of neuropathy and retinopathy was not. In multivariate analysis adjusting age, BMI, HbA1c and use of GLP-1 receptor agonist, CSIS were significantly associated with longer duration of DM (β=0.003, SD=0.001, p=0.01), and diabetic nephropathy(OR=1.95, 95% CI:1.01-3.71). Neuropathy and retinopathy had no significant association with CSIS. Our results suggest that not only in the end stage renal disease, earlier stage of diabetic nephropathywith proteinuria might be the risk of indigestionsymptoms in patients with diabetes mellitus. Disclosure Y. Namiki: None. E. Yamada: None. Y. Takano: None. H. Takamine: None. H. Sasaki: None. K. Inazumi: None. T. Minami: None. S. Ito: None. N. Mantani: None. T. Iwasaki: None. M. Yamada: None. A. Nakajima: None. Y. Terauchi: Research Support; Self; MSD K.K.. Speaker9s Bureau; Self; MSD K.K.. Advisory Panel; Self; MSD K.K.. Research Support; Self; Ono Pharmaceutical Co., Ltd.. Speaker9s Bureau; Self; Ono Pharmaceutical Co., Ltd.. Research Support; Self; Novartis Pharma K.K., Boehringer Ingelheim GmbH. Speaker9s Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Boehringer Ingelheim GmbH. Research Support; Self; Mitsubishi Tanabe Pharma Corporation. Speaker9s Bureau; Self; Mitsubishi Tanabe Pharma Corporation. Advisory Panel; Self; Mitsubishi Tanabe Pharma Corporation. Research Support; Self; Daiichi Sankyo Company, Limited. Speaker9s Bureau; Self; Daiichi Sankyo Company, Limited. Advisory Panel; Self; Daiichi Sankyo Company, Limited. Research Support; Self; Sanwa Kagaku Kenkyusho Co., Ltd.. Speaker9s Bureau; Self; Sanwa Kagaku Kenkyusho Co., Ltd.. Research Support; Self; Novo Nordisk Inc.. Speaker9s Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Eli Lilly and Company. Speaker9s Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Sanofi. Speaker9s Bureau; Self; Sanofi. Advisory Panel; Self; Sanofi. Research Support; Self; Sumitomo Dainippon Pharma Co., Ltd.. Speaker9s Bureau; Self; Sumitomo Dainippon Pharma Co., Ltd.. Research Support; Self; Shionogi & Co., Ltd.. Speaker9s Bureau; Self; Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., Astellas Pharma US, Inc., AstraZeneca. Advisory Panel; Self; AstraZeneca, Teijin Pharma Limited. U.N. Osada: None.